Stock INCY INCYTE CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

News Incyte Corporation

Equities

INCY

US45337C1027

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		After market 05:36:29 pm
51.18 USD -1.08% Intraday chart for Incyte Corporation 51.15 -0.06%
Apr. 24 Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating MT
Apr. 23 Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
"Shadow Trading" Is Insider Trading: Jury Establishes Liability In Historic Shadow Trading Case
AQ
Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating
MT
Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
BU
SEC Wins Novel 'Shadow Trading' Trial Against Biopharma Executive
AQ
Incyte Corporation entered into a definitive agreement to acquire Escient Pharmaceuticals, Inc. from a group of shareholders for $750 million.
CI
BMO Capital Adjusts Price Target on Incyte to $56 From $64
MT
Incyte to Report First Quarter Financial Results
BU
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(4) - March 29, 2024
AQ
Incyte, China Medical System Sign Collaboration, License Agreement
MT
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
BU
Incyte Corporation and China Medical System Holdings Limited Announce Collaboration and License Agreement for Povorcitinib, an Oral Jak1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
CI
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
Trial of Insider Trading Case Against Former Medivation Employee Begins in California
MT
SEC v Panuwat: The SEC's Novel "Shadow Trading" Insider Trading Case Goes To Trial
AQ
Incyte's Povorcitinib Potentially Suited for Hidradenitis Suppurativa, Prurigo Nodularis, RBC Says
MT
Transcript : Incyte Corporation - Shareholder/Analyst Call
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
BU
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
BU
Incyte Announces New Results from A Phase 2 Study Evaluating the Efficacy and Safety of Twice-Daily Ruxolitinib Cream 1.5% (Opzelura®) in Adult Patients with Hurley Stage 1 or 2 (Mild-To-Moderate) Hidradenitis Suppurativa (HS)
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INCY Stock
  4. News Incyte Corporation